Exodus Point Capital Management, LP Tricida, Inc. Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$7.31 - $11.85 $985,804 - $1.6 Million	-134,857 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$7.35 - $10.63 $700,146 - $1.01 Million	95,258 Added 240.56%	134,857 $1.11 Million
Q4 2021 Feb 11, 2022	BUY	$4.19 - $9.56 $165,919 - $378,566	39,599 New	39,599 $379,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $96,903 - $126,300	-27,220 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.95 - $5.41 $107,519 - $147,260	27,220 New	27,220 $118,000

Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $126,498 - $273,838	-28,947 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $247,786 - $779,542	28,947 New	28,947 $262,000
Q1 2020 May 15, 2020	SELL	$18.43 - $38.04 $567,478 - $1.17 Million	-30,791 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $383,527 - $566,350	12,957 Added 72.65%	30,791 $1.16 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $532,701 - $752,951	17,834 New	17,834 $551,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.